ANZUP 2023 | Genitourinary cancer trials at ANZUP 2023: SUBDUE-1 and ZiPUP

Dickon Hayne, MBBS, MD, FRCS, FRACS, The University of Western Australia, Perth, Australia, gives an overview of recent trials in bladder urothelial and penile cancers, including the Phase Ib SUBDUE-1 trial (ACTRN12620000063910) of sub-urothelial durvalumab in patients with patients with non-muscle-invasive bladder cancer (NMIBC), and the Phase I ZiPUP trial (NCT05046665) of 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in patients with urothelial cancer. Dr Hayne additionally highlights the ACCEPT-U registry, which will collate cystectomy data, unmet supportive care needs in patients with penile cancer, as well as the potential role of artificial intelligence (AI) in analyzing imaging scans. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.